Objective: We wanted to retrospectively evaluate the long-term therapeutic results of iliac arterial stent placement that was done in a single institution for 10 years.
Materials And Methods: From May 1994 to April 2004, 206 patients who underwent iliac arterial stent placement (mean age; 64+/-8.8) were followed up for evaluating the long term stent patency. Combined or subsequent bypass surgery was performed in 72 patients. The follow up period ranged from one month to 120 months (mean; 31+/-25.2 months). The factors that were analyzed for their effect on the patency of stents were age, the stent type and diameter, the lesion site, lesion shape, lesion length, the Society of Cardiovascular and Interventional Radiology criteria, the total run off scores, the Fontaine stage and the cardiovascular risk factors (diabetes mellitus, hypertension and smoking). Follow-up included angiography and/or CT angiography, color Doppler sonography and clinical evaluation with the ankle-brachial index.
Results: Two hundred and eighty-four stents were placed in 249 limbs of 203 patients. The technical success rate was 98% (203/206). The primary patency rates of the stents at 3, 5, 7 and 10 year were 87%, 83%, 61% and 49%, respectively. One hundred seventy-seven patients maintained the primary stent patency until the final follow up and 26 patients showed stenosis or obstruction during the follow up. Secondary intervention was performed in thirteen patients. Lesions in the external iliac artery (EIA) or lesions in both the common iliac artery (CIA) and EIA were a poor prognostic factor for stent patency. The run off score and stent diameter also showed statistically significant influence on stent patency. The overall complication rate was 6%.
Conclusion: Iliac arterial stent placement is a safe treatment with favorable long term patency. Lesions in the EIA or lesions in both the EIA and CIA, poor run off vessels and a stent having the same or a larger diameter than 10 mm were the poor prognostic factors for long term stent patency.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684973 | PMC |
| http://dx.doi.org/10.3348/kjr.2005.6.4.256 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cangrelor Use for Viabahn Stent Graft Patency as Bridge to Coronary Artery Bypass Graft Surgery.
J Pharm Pract
January 2025
Department of Cardiothoracic Surgery, Jefferson Health Abington Hospital, Abington, PA, USA.
Utilization of cangrelor following coronary artery stent placement as a bridge to cardiac surgery has been previously described in the literature. However, the use of cangrelor as bridge therapy to cardiac surgery for endovascular revascularization is lacking. We describe a case involving a 47-year-old female who developed a left lower extremity tibioperoneal trunk non-obstructing arterial dissection following extracorporeal membrane oxygenation decannulation, requiring repair with a Viabahn endoprosthesis.
View Article and Find Full Text PDFIntroduction: Auto-expandable ureteral stents can be an alternative to percutaneous nephrostomy (PCN) in refractory ureteral stenosis. Our aim is to analyse results and complications of ureteral stents in our centre.
Methods: Retrospective review of OptiMed® expandable ureteral stents placed in our centre (1996-2022).
Peritherapeutic intra-arterial flow changes predict long-term stent patency in patients with severe intracranial artery stenosis receiving PTAS.
Eur J Radiol
December 2024
Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address:
Background And Purpose: The quantitative intra-arterial flow dynamics following percutaneous transluminal angioplasty and stenting (PTAS) for severe intracranial artery stenosis have never been investigated. We aimed to evaluate peritherapeutic intracranial artery flow dynamics following PTAS with quantitative magnetic resonance angiography (qMRA) to predict long-term stent patency.
Design: This is a prospective, single-center study.
Novel Use of Drug-eluting Stent in Otologic Surgery to Prevent Restenosis.
Ann Otol Rhinol Laryngol
January 2025
Department of Otolaryngology-Head and Neck Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Objectives: The primary objective of this case series is to assess the effectiveness of the off-label use of the PROPEL drug-eluting stent, traditionally FDA-approved for sinus surgery, in preventing restenosis following canalplasty in patients with chronic otologic conditions or congenital anomalies. The stent provides both mechanical support to maintain canal patency and localized steroid delivery to reduce inflammation and scarring.
Methods: Four patients with various otologic conditions underwent canalplasty, followed by the placement of drug-eluting stents into the external auditory canal.
Direct percutaneous puncture of occluded venous stents as an adjunctive technique to restore patency.
CVIR Endovasc
January 2025
Department of Radiology, Section of Vascular and Interventional Radiology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA, 98195, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!